Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Zimmer Biomet Holdings is conducting a randomized controlled trial titled ‘Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA.’ The study aims to evaluate the safety, performance, and clinical benefits of both cementless and cemented knee systems, which is significant for improving treatment options for various knee conditions.
Intervention/Treatment: The study tests two interventions: the Cementless Persona Knee System and the Cemented Persona Knee System. Both are total knee systems designed for knee joint replacement, targeting conditions like osteoarthritis and rheumatoid arthritis.
Study Design: This interventional study uses a randomized, parallel assignment model. It employs single masking, where participants are unaware of their group allocation until after surgery. The primary purpose is treatment-focused, aiming to compare the two knee systems’ effectiveness.
Study Timeline: The study began on October 18, 2022, with the latest update submitted on October 23, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: This clinical update could influence Zimmer Biomet’s stock performance positively by showcasing innovation in knee replacement technology. As the company competes in a robust orthopedic market, advancements in product efficacy may enhance investor confidence and market position.
The study is currently recruiting, with further details available on the ClinicalTrials portal.